288. 自己免疫性後天性凝固因子欠乏症 Autoimmune acquired coagulation factor deficiency Clinical trials / Disease details
臨床試験数 : 206 / 薬物数 : 231 - (DrugBank : 28) / 標的遺伝子数 : 10 - 標的パスウェイ数 : 21
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04567511 (ClinicalTrials.gov) | September 1, 2021 | 29/7/2020 | Hemlibra in Mild Hemophilia A | Prospective, Single-Arm, Open-Label Use of Hemlibra (Emicizumab) in the Treatment of Mild Hemophilia A | Factor VIII Deficiency, Congenital | Drug: Emicizumab | Indiana Hemophilia &Thrombosis Center, Inc. | Genentech, Inc. | Recruiting | 5 Years | 45 Years | Male | 40 | Phase 4 | United States |
| 2 | EUCTR2019-004430-42-AT (EUCTR) | 22/06/2021 | 22/04/2021 | Evaluation of the effect of emicizumab in patients suffering from acute bleeds with previously no family history. | Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial | Acquired Hemophilia A (AHA) MedDRA version: 22.1;Level: LLT;Classification code 10053761;Term: Acquired hemophilia with anti FVIII, XI, or XIII;System Organ Class: 100000004851 MedDRA version: 20.0;Classification code 10053760;Term: Acquired hemophilia;System Organ Class: 100000004851;Therapeutic area: Body processes [G] - Immune system processes [G12] | Trade Name: Hemlibra® INN or Proposed INN: Emicizumab Other descriptive name: RO5534262 EMICIZUMAB | GWT-TUD GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 47 | Phase 2 | Austria;Germany | ||
| 3 | EUCTR2019-004430-42-DE (EUCTR) | 25/01/2021 | 20/11/2020 | Evaluation of the effect of emicizumab in patients suffering from acute bleeds with previously no family history. | Emicizumab in Patients with Acquired Hemophilia A: Multicenter, Single-Arm, Open-Label Clinical Trial | Acquired Hemophilia A (AHA) MedDRA version: 22.1;Level: LLT;Classification code 10053761;Term: Acquired hemophilia with anti FVIII, XI, or XIII;System Organ Class: 100000004851 MedDRA version: 20.0;Classification code 10053760;Term: Acquired hemophilia;System Organ Class: 100000004851;Therapeutic area: Body processes [G] - Immune system processes [G12] | Trade Name: Hemlibra® INN or Proposed INN: Emicizumab Other descriptive name: RO5534262 EMICIZUMAB | GWT-TUD GmbH | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 47 | Phase 2 | Austria;Germany |